Toggle light / dark theme

Yale researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.

The study was led by Andre Levchenko, the John C. Malone Professor of Biomedical Engineering and director of the Yale Systems Biology Institute at Yale’s West Campus. It was published June 26 in the journal Nature Communications. Levchenko is a member of the Yale Cancer Center.

One way metastasis occurs is through (EMT), a process that breaks neighboring apart from each other and sets them in motion. It’s been long assumed that chemical signals or in the cells trigger EMT. But Levchenko’s research team found that it could be caused by a simple change in the texture of the extracellular matrix (ECM), which acts as a scaffold for cells. They discovered that an alignment of the matrix’s fibers (a common biological occurrence) can trigger the EMT process without or other stimuli.

(CNN) — Exposure to a chemical commonly used to reduce bacterial contamination in cosmetics, toothpaste and products like toys and clothing may come with an unintended risk — osteoporosis. That’s according to a study in Tuesday’s Journal of Clinical Endocrinology & Metabolism.

The study looked at data from 1,848 women between 2005 and 2010 and found that women who had higher levels of triclosan in their urine were more likely to develop osteoporosis later on in life. Osteoporosis is a metabolic bone disease in which a person loses bone mineral density. With the bones weakened, it puts a person at an increased risk for fractures, back pain and loss of height.

This the first such study to find this connection, researchers said.

Today, we want to highlight a new publication that looks at cytomegalovirus (CMV) and its potential role in the development of metabolic syndrome, the precursor to type 2 diabetes.

What is cytomegalovirus?

CMV is part of the β-subfamily of herpes viruses, a family of viruses that are believed to have been co-evolving with their hosts for around 180 million years [1]. CMV is spread primarily by exposure to infected secretions and subsequent mucosal contact, which then leads to the acute infection of various cell types. After this acute infection, in which the virus spreads, it enters a dormant state in the body.

Another great addition to #RAADfest2019 #cureaging #NAD #superlongevity


Dr. Nichola Conlon, Nuchido CEO & Co-founder, chats with James Strole, Director of the Coalition for Radical Life Extension, about what she’s bringing to RAADfest 2019: Increasing NAD+ levels in middle-aged people to a level comparable with people 17 years younger with the data to back it up.

Nuchido has pioneered the use of systems pharmacology and clinical research to boost and maintain NAD. In a scientific world-first, the team achieved the biggest increase of NAD in humans reported by any scientific group.

Hear what she has to share, and meet her at RAADfest 2019:

Two recent studies highlight novel ways to combat pattern hair loss in men and women using small molecules such as JAK inhibitors that reawaken dormant hair follicles, as well as stem cell therapies aimed at growing new follicles.

In the first study, researchers led by Angela Christiano, Ph.D., the Richard & Mildred Rhodebeck Professor of Dermatology at Columbia University Vagelos College of Physicians and Surgeons, discovered previously unknown cells that keep mouse follicles in a resting state and show that inhibiting the activity of these cells can reawaken dormant follicles.

In a second study, Christiano’s team created a way to grow human hair in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair-growth drugs.

Individuals that are experiencing frequent migraines, may soon receive access to a new class of medications.

A pair of large studies showed that two drugs have the ability to reduce the frequency of the migraine attacks, without any side effects. The researchers report in the New England Journal of Medicine that the drugs offer the first ever migraine treatment that is aimed at the disorder itself, instead of the symptoms.

Current migraine treatments consist of drugs that are designed to treat epilepsy, depression and high blood pressure. Peter Goadsby, an author of one of the studies in question and a professor at King’s College in London says that they give the patients a choice between antidepressants that will make them sleepy, and a beta blocker, which will make them feel tired.